# EMBRACA (NCT01945775)

> A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01945775
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Pfizer
- Conditions: Breast Neoplasms; BRCA 1 Gene Mutation; BRCA 2 Gene Mutation
- Interventions: talazoparib; Physician's-Choice
- Enrollment: 431
- Primary outcome: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment

## Commentary we found

- YouTube: 11
- Podcasts: 11
- X threads: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=embraca-nct01945775

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01945775", "email": "<work email>"}; the inbox owner confirms by the emailed link.